Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calaspargase pegol - Servier

Drug Profile

Calaspargase pegol - Servier

Alternative Names: ASPARLAS; Cal-PEG; EZN-2285; Oncaspar-IV; S9-5015; SC-PEG E. coli L-asparaginase; Scalasparagase pegol; SHP-663

Latest Information Update: 07 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enzon Pharmaceuticals
  • Developer Children's Oncology Group; Dana-Farber Cancer Institute; Leadiant Biosciences; National Cancer Institute (USA); Servier
  • Class Amidohydrolases; Antineoplastics; Polyethylene glycols
  • Mechanism of Action Aspartate-ammonia ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Haematological malignancies
  • No development reported Acute myeloid leukaemia

Most Recent Events

  • 30 Apr 2022 Phase-II clinical trials in Haematological malignancies (IV) before April 2022 (Servier pipeline, June 2022)
  • 28 May 2019 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Unknown (IV)
  • 08 Jan 2019 Shire has been acquired and merged into Servier
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top